Actavis Launches Generic Version of Temovate® (clobetasol cream 0.05%)

DUBLIN, March 9, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that it has launched a generic version of Fougera's Temovate® (clobetasol cream 0.05%) in the U.S. The launch strengthens Actavis' growing portfolio of valuable topical products and demonstrates the deep expertise of the Company's global R&D and supply chain capabilities.

Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO

Temovate® is a high-potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

For the 12 months ended January 15, 2015, Temovate® had total U.S. brand and generic sales of approximately $185 million, according to IMS Health data.

About Actavis

About Actavis plc (NYSE:ACT), headquartered in Dublin, Ireland, is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world.

Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women's health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. The Company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.

For more information, visit Actavis' website at www.actavis.com.

Cautionary Statement Regarding Forward-Looking Statements

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Actavis' current expectations depending upon a number of factors affecting Actavis' business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Actavis' products; risks associated with acquisitions, mergers and joint ventures; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Actavis' periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis' Annual Report on Form 10-K for the year ended December 31, 2014. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements.

Temovate® is a registered trademark of Glaxo SmithKline.

CONTACTS:
Investors:

Lisa DeFrancesco

(862) 261-7152

Media:

Charlie Mayr

(862) 261-8030

David Belian

(862) 261-8141

Suggested Articles

After a slow start, Teva's Ajovy launch is improving following the FDA approval for an autoinjector.

After Trump's "Buy American" executive order for essential medicines, the pharma industry is pushing back.

The U.S. is slamming the brakes on its $765 million loan to Kodak amid insider trading allegations and questions about its fitness for the job.